Crescent Biopharma (CBIO) Profit After Tax (2013 - 2026)

Crescent Biopharma (CBIO) has reported Profit After Tax for 14 consecutive years, with -$24.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax fell 13.98% year-over-year to -$24.8 million; the TTM figure through Jun 2026 stood at -$96.0 million (down 48.58% YoY), while the FY2025 annual figure was -$153.9 million, down 761.6% from the prior year.
• Profit After Tax slipped to -$24.8 million in Q2 2026 per CBIO's latest filing, from -$23.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$8.3 million in Q2 2023 and bottomed at -$24.8 million in Q2 2026.
• Historically, Profit After Tax has averaged -$14.7 million across 5 years, with a median of -$12.0 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax soared 50.82% — and 2025, when it tumbled 150.47%.
• Crescent Biopharma's Profit After Tax stood at -$10.2 million in 2022, then grew by 11.38% to -$9.1 million in 2023, then sank by 96.8% to -$17.9 million in 2024, then plunged by 30.41% to -$23.3 million in 2025, then slipped by 6.6% to -$24.8 million in 2026.
• Business Quant data shows CBIO's Profit After Tax at -$24.8 million in Q2 2026, -$23.3 million in Q1 2026, and -$23.3 million in Q4 2025.